



For Immediate Release

CyGenics Ltd becomes CordLife Ltd

Key Points:

- Completion of renaming process to CordLife Ltd
- ASX code changed to **CBB**
- Focus on cord blood banking business

19th April 2007 – Leading healthcare company CordLife Ltd today announced the completion of its renaming process from CyGenics Ltd to CordLife Ltd, in line with the shareholders' approval at the Extraordinary General Meeting on 21st March 2007.

Effective today, the company's name is now officially CordLife Ltd, and the ASX code has been changed from **CYN** to **CBB**.

This name change to CordLife Ltd is in line with the company's focus on its rapidly growing, revenue-generating cord blood banking business and its plans to partner out its stem cell therapy and technology development businesses.

"CordLife Ltd has been focusing on growing the cord blood banking business in the Asia Pacific region and in managing our strong portfolio of technologies," said Steven Fang, Group CEO. "We plan to be the largest regional cord blood bank in this region. With facilities in Hong Kong, Singapore, Sydney, and with Jakarta and Kolkata coming on stream this year, we are well on our way."

About CordLife

CordLife (ASX: CBB), formerly known as CyGenics, is a healthcare company focused on tissue and cord blood banking. CordLife owns and operates the largest network of private cord blood banks in the Asia Pacific region and has a portfolio of stem cell technology related investments. Its major subsidiary, CordLife Pte Ltd, is an Asian regional cord blood bank that operates a state-of-the-art AABB (formerly known as the American Association of Blood Banks) accredited facility in Singapore and a separate compliant facility in Hong Kong. CordLife's facility was the first private cord blood bank to be set up in Singapore, and among the first in Asia. It is the only AABB-accredited cord blood bank in this region. These banking facilities comprise full processing and cryogenic storage capabilities. Web site: www.cordlife.com. Its subsidiary, BioCell Pty Ltd, is an Australian cord blood bank. BioCell has a strategic relationship with the Sydney Adventist Hospital. The cord blood units are processed and stored in the Therapeutic Goods Administration (the Australian regulator) accredited cord blood banking facility in the Hospital. Web site: www.biocellaustralia.com. CordLife India and Indonesia subsidiaries are currently building new facilities, in preparation for a marketing launch in mid 2007.

About Cord Blood Stem Cells

Cord blood stem cells are most commonly used to treat several different types of blood cancers, such as acute leukemias, other blood disorders and various inherited disorders. Stem cells from cord blood



are described as 'adult' to distinguish them from the stem cells derived from embryos. Research into the use of these cells has shown that adult stem cells can also be used to treat autoimmune diseases such as lupus, multiple sclerosis, Crohn's disease, and rheumatoid arthritis. Early clinical studies also suggest that they can help avert corneal degeneration and restore vision in cases of blindness, can help to restore proper cardiac function to heart attack sufferers and can improve movement in spinal cord injury patients. Stem cells from cord blood have a number of advantages over stems cells collected later in life, including a lower risk of rejection.

For more information, please contact:

Ian Brown, CIO
Ph: +61 (0)3 9642 5580
Mob: +61 (0)438 565 212
Email: ibrown@cordlife.com

Steven Fang, CEO
Ph: +61 (0)3 9642 5580
Mob: +61 (0)400 933 243
Email: sfang@cordlife.com

Ronald Hee
Mob: +65 9061 9098
Email: rhee@cordlife.com